source
- Novartis' experimental drug fails pivotal trial for rare neuromuscular diseaseNovartis reported that its experimental therapy for a rare neuromuscular disorder did not improve muscle function in a pivotal study, missing its primary endpoints. The failure represents the comp…
- Novartis' del-desiran misses primary goal in late-stage myotonic dystrophy trialNovartis announced that its experimental RNA drug del-desiran did not achieve the primary endpoint in a late-stage study of myotonic dystrophy type 1, a rare muscle‑weakening disease. The trial me…